首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

2001249

全球胜肽类药物偶联物市场：市场机会、药物销售、专利、定价、剂量、专有技术和临床试验展望（2031 年）

Global Peptide Drug Conjugate Market Opportunity, Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Clinical Trials Outlook 2031

出版日期: 2026年03月01日 | 出版商:

KuicK Research | 英文 160 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球胜肽类药物偶联物市场研究结果及亮点：商业机会、药物销售、专利、定价、剂量、专有技术和临床试验展望（2031 年）报告：

全球胜肽类药物偶联物市场机会：到2031年将超过15亿美元
2021年至2025年全球胜肽类药物偶联物市场成长：复合年增长率超过14%
深入了解已通过核准肽类药物偶联物的剂量、定价和销售情况。
全面深入了解临床试验中的胜肽-药物偶联物：超过50种胜肽偶联物
依公司、国家、适应症和阶段分析全球胜肽类药物偶联物临床试验。
肽类药物偶联物开发中专有技术的深入剖析：18 项技术

肽类药物偶联物的必要性及本报告的意义

胜肽-药物偶联物（PDCs）正日益成为最有前景的新兴治疗方法之一，能够克服传统药物递送系统的一些主要限制。肽-药物偶联物可用于解决全身毒性、选择性不足、组织渗透性差、抗药性等问题。

肽-药物偶联物因其能够透过精准标靶化改善患者的临床疗效，尤其是在癌症治疗领域，而备受关注。然而，肽-药物偶联物的潜力不仅限于癌症治疗；它们还可用于治疗其他疾病，例如感染疾病、发炎和代谢紊乱，使其成为广泛应用的药物递送系统。

截至2026年3月，全球胜肽-药物偶联物市场仍处于早期阶段，但发展迅速。目前已通过核准的治疗方法有限，且仅有概念验证（PoC）证明了其临床和商业性可行性。同时，在胜肽化学和药物偶联技术创新的推动下，大量肽-药物偶联物正在研发和商业化过程中。

本报告整合了科学、临床、技术和商业性等多个方面，全面展现了全球胜肽类药物偶联物市场的概况。旨在帮助製药公司和投资者了解这个新兴且不断发展的治疗领域的趋势和机会。

报告中包含对临床试验的深入分析

临床开发是肽类药物偶联物的主要成长要素，其多阶段研发管线正在稳步扩展，反映出人们对其治疗潜力的信心日益增强。肿瘤学仍然是主要研究方向，肽类药物偶联物靶向肿瘤中过度表达的受体，从而实现精准给药，提高安全性和疗效。后期临床试验中令人鼓舞的结果进一步凸显了这项潜力。除癌症外，研究范围正在扩展到感染疾病疾病和发炎性疾病，胜肽类药物偶联物旨在选择性地靶向感染或活化的细胞，从而增强治疗效果，同时最大限度地减少全身暴露和相关副作用。

本报告对各阶段的临床试验进行了详细评估，涵盖从早期探索性研究到后期验证性试验的各个方面。报告分析了研究设计、患者选择、给药策略和联合治疗等关键要素，旨在识别新兴趋势和未来发展方向。多种候选药物进入后期研发阶段，显示此类治疗药物正日趋成熟。

专注于胜肽类药物偶联物研发的主要企业

肽类药物偶联物市场的竞争格局是由老牌製药公司和创新生物技术公司之间的合作所推动的。诺华等主要企业发挥了先锋作用，尤其是在放射性标记肽疗法和标靶癌症治疗方面取得了显着进展，为该领域树立了重要的标竿。同样，Oncopeptides公司也为骨髓恶性肿瘤肽治疗方法发展做出了贡献。

同时，新兴的生物技术产业正加速胜肽类药物偶联物（PDM）产业的发展。 Bicycle Therapeutics、Cybrexa Therapeutics和PepGen等公司正积极致力于开发新型胜肽平台和连接子技术，并改进靶向药物递送平台。这些措施不仅增强了PDM产业的实力，也拓展了PDM的应用范围，使其能够用于治疗包括非癌症疾病在内的多种疾病。

肽类药物偶联物产业的竞争格局是由製药和生物技术两大产业共同努力塑造的。这两个产业正致力于创新和策略扩张，尤其是在研发领域，以期在这个新兴产业中奠定坚实的基础。

技术平台、合作伙伴关係和协议

技术创新是胜肽-药物偶联物开发的关键要素，胜肽设计、偶联化学和连接子技术的进步显着提高了药物偶联物的稳定性、特异性和疗效。胜肽-药物偶联物技术的新方法包括增强结合亲和性、优化药物控释和改善药物动力学。肽-药物偶联物的一项关键创新是使用“智慧连接子”，它能够响应酶和pH等触发因素释放药物，同时保持药物在循环系统中的稳定性。另一项创新是胜肽的环化和非天然胺基酸的使用，这透过增强胜肽对酵素降解的抵抗力来提高其稳定性。

影响胜肽类药物偶联物技术发展的另一个重要因素是合作研究和策略伙伴关係。透过跨领域合作，企业可以提高研发效率并增强技术能力。此外，随着该领域高度协作的创新进程不断推进，授权协议也日益普遍。

一份概述胜肽药物偶联物片段未来发展方向的报告。

技术创新在胜肽-药物偶联物的开发中发挥核心作用，胜肽设计、偶联化学和连接子技术的进步显着提高了药物偶联物的稳定性、特异性和治疗效果。现代策略着重于增强结合亲和性、优化药物控释、改善药物动力学。一项关键创新是使用“智慧连接子”，这种连接子能够响应酶或pH值变化等触发因素释放活性成分，同时保持药物在循环系统中的稳定性。此外，肽环化和非天然氨基酸的引入增强了药物偶联物对酶降解的抵抗力，并提高了整体稳定性。

总之，在加大投资、临床检验和技术创新的支持下，肽-药物偶联物有望在下一代标靶治疗的开发中发挥重要作用，用于治疗多种疾病。

Global Peptide Drug Conjugate Market Opportunity: > USD 1.50 Billion By 2031
Global Peptide Drug Conjugate Market Growth 2021 -2025: > 14% CAGR
Approved Peptide Drug Conjugates Dosage, Pricing & Sales Insight
Comprehensive Insight On Peptide Drug Conjugate In Clinical Trials: > 50 Peptide Conjugates
Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
Insight On Peptide Drug Conjugate Development Proprietary Technologies: 18 Technologies

Need For Peptide Drug Conjugates & Why This Report?

Peptide Drug Conjugates (PDCs) are increasingly proving to be one of the most promising emerging therapeutics that can address some of the major limitations associated with conventional drug delivery systems. Peptide Drug Conjugates can be used to overcome issues such as systemic toxicity, lack of selectivity, poor tissue penetration, and development of drug resistance.

Significant interest has been generated in Peptide Drug Conjugates, especially for cancer therapy, where precise targeting can improve clinical outcomes for patients. However, potential for Peptide Drug Conjugates is not limited to cancer therapy, but can be used to treat other diseases such as infections, inflammation, and metabolic diseases, making them a broad-spectrum drug delivery system.

As of March 2026, the global Peptide Drug Conjugate market remains in an early but rapidly evolving phase, with a limited number of approved therapies providing proof-of-concept for clinical and commercial viability. At the same time, there is a strong pipeline of Peptide Drug Conjugates that are being developed and commercialized based on innovations in peptide chemistry and drug conjugation.

This report presents an all-inclusive view of the global Peptide Drug Conjugate market, integrating scientific, clinical, technical, and commercial aspects. It is designed to help pharmaceutical companies and investors to understand the developments and emerging opportunities in this new and expanding area of therapeutics.

Clinical Trials Insight Included In Report

Clinical development is a key growth driver for Peptide Drug Conjugates, with a steadily expanding pipeline across multiple stages reflecting increasing confidence in their therapeutic potential. Oncology remains the primary focus, where Peptide Drug Conjugates target overexpressed tumor receptors to enable precise drug delivery with improved safety and efficacy. Encouraging outcomes from late-stage trials further support their promise. Beyond cancer, research is extending into infectious and inflammatory diseases, where Peptide Drug Conjugates are designed to selectively target infected or activated cells, enhancing treatment effectiveness while minimizing systemic exposure and associated side effects.

The report provides a detailed assessment of clinical trials across all phases, including early-stage exploratory studies and late-stage confirmatory trials. Key aspects such as study design, patient selection, dosing strategies, and combination approaches have been analyzed to identify emerging trends and future development pathways. The progression of multiple candidates into advanced stages of development highlights the increasing maturity of this therapeutic class.

Major Companies Active In R&D Of Peptide Drug Conjugates

The competitive landscape of the Peptide Drug Conjugate market is driven by the combined efforts of established pharmaceutical companies and innovative biotechnology firms. Major players such as Novartis have played a pioneering role, particularly through advancements in radiolabeled peptide therapeutics and targeted oncology treatments, setting important benchmarks for the field. Similarly, Oncopeptides has contributed to the development of peptide-based therapies in hematological malignancies.

On the other hand, the emerging biotechnology industry is accelerating the progress of the Peptide Drug Conjugate industry. Companies like Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen are actively involved in the development of novel peptide platforms, linker technologies, and improving targeted drug delivery platforms, which are not only strengthening the Peptide Drug Conjugate industry but also expanding the scope of Peptide Drug Conjugates for the treatment of a wide range of diseases, including those other than cancer.

The competitive environment of the Peptide Drug Conjugate industry is shaped by the cumulative efforts of the pharmaceutical and biotechnology industry, which is focused on innovation and strategic expansion, especially in the form of research and development to consolidate a strong footing in this emerging industry.

Technology Platforms, Collaborations & Agreements

Technological innovation is an integral part of Peptide Drug Conjugate development, as advancements in peptide design, conjugate chemistry, and linker technology improve stability, specificity, and efficacy. New approaches in Peptide Drug Conjugate technology involve improvement in binding affinity, optimization of controlled drug release, and pharmacokinetics. The major technological innovation in Peptide Drug Conjugate is the use of smart linkers that remain stable in circulation but can release drugs in response to triggers such as enzymes or pH. Another innovation is peptide cyclization and the use of non-natural amino acids to improve stability by resisting enzymatic degradation.

Another factor that is significantly impacting Peptide Drug Conjugate technology is collaborations and strategic partnerships. By leveraging partnerships in various fields of study, companies are able to improve efficiency in their research and increase their technological capabilities. Licensing agreements are also becoming increasingly prevalent in this field as it is a highly collaborative innovation process.

Report Indicating Future Direction Of Peptide Drug Conjugate Segment

Technological innovation is central to Peptide Drug Conjugate development, with advances in peptide design, conjugation chemistry, and linker technologies enhancing stability, specificity, and therapeutic performance. Modern strategies focus on improving binding affinity, optimizing controlled drug release, and refining pharmacokinetics. A key innovation is the use of smart linkers that remain stable in circulation but release payloads in response to triggers like enzymes or pH changes. Additionally, peptide cyclization and incorporation of non-natural amino acids improve resistance to enzymatic degradation and enhance overall stability.

In conclusion, peptide drug conjugates, backed by increasing investment, clinical validation, and technological innovation, are likely to play a major role in the development of the next generation of targeted therapies for a wide range of diseases.

1. Research Methodology

2. Introduction To Peptide Drug Conjugates

2.1 Overview
2.2 History & Evolution
2.3 Peptide Drug Conjugates v/s Antibody Drug Conjugates

3. Peptide Drug Conjugates - Structural Components & Mechanism of Action

3.1 Components
3.2 Mechanism of Action

4. Peptide Drug Conjugates Research & Development Trends By Indication

4.1 Cancer
4.2 Microbial Infections
4.3 Others

5. Global Peptide Drug Conjugates Market Outlook

5.1 Current Clinical & Market Trends
5.2 Future Market Outlook & Opportunities
5.3 Peptide Drug Conjugate Development Proprietary Technologies & Methodologies

6. Global Peptide Drug Conjugates Research & Market Trends By Region

6.1 US
6.2 China
6.3 Japan
6.4 Europe
6.5 South Korea

7. Lutathera - Clinical & Commercial Insight

7.1 Overview, Availability & Patent Insight
7.2 Dosage & Price Analysis
7.3 Sales Analysis

8. Pepaxto/Pepaxti - Clinical & Commercial Insight

8.1 Overview & Availability
8.2 Dosage Analysis
8.3 Sales Analysis

9. Global Peptide Drug Conjugates Clinical Pipeline Overview

9.1 By Phase
9.2 By Company
9.3 By Country
9.4 By Indication
9.5 By Priority Status

10. Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III
10.7 Preregistration

11. Marketed Peptide Drug Conjugates Clinical Insight

12. Competitive Landscape

12.1 Angiochem
12.2 Avacta
12.3 Bicycle Therapeutics
12.4 Cybrexa Therapeutics
12.5 ITM Solucin
12.6 Novartis
12.7 Oncopeptides
12.8 PepGen Corporation
12.9 Soricimed Biopharma
12.10 Theratechnologies

简介目录图表

List of Figures

Figure 2-1: Timeline Of Key Events In Development Of Peptide Drug Conjugates
Figure 3-1: Peptide Drug Conjugates - Components
Figure 3-2: Peptide Drug Conjugate - Mechanism Of Action
Figure 4-1: Approved Peptide Drug Conjugates
Figure 4-2: TH1902-CTR-0001 Phase I (NCT04706962) Study - Initiation & Completion Year
Figure 4-3: CBX-12-101 Phase I/II (NCT04902872) Study - Initiation & Completion Year
Figure 4-4: CBX-12-201 Phase II (NCT06315491) Study - Initiation & Completion Year
Figure 4-5: NCI-2022-11034 Phase I (NCT05691517) Study - Initiation & Completion Year
Figure 4-6: Duravelo-1 Phase I/II (NCT04561362) Study - Initiation & Completion Year
Figure 4-7: Duravelo-2 Phase II/III (NCT06225596) Study - Initiation & Completion Year
Figure 4-8: BT5528-100 Phase I/II (NCT04180371) Study - Initiation & Completion Year
Figure 4-9: BT5528-201 Phase II (NCT07450859) Study - Initiation & Completion Year
Figure 4-10: ALS-6000-101 Phase I (NCT04969835) Study - Initiation & Completion Year
Figure 4-11: PQ203-001 Phase I (NCT07190469) Study - Initiation & Completion Year
Figure 4-12: Rational Design Strategy For Anti-Infective PDCs
Figure 5-1: Global - Peptide drug Conjugates Market (US$ Million), 2018-2025
Figure 5-2: Global - Peptide drug Conjugates Market (US$ Million), 2026-2031
Figure 5-3: Potential Future Directions in Peptide-Drug Conjugate Development
Figure 5-4: alphalex Platform - Cybrexa
Figure 5-5: Decoy Platform - Candidate Life Cycle
Figure 5-6: Decoy Platform - Modular Peptide Engineering & Conjugation Chemistry
Figure 5-7: Decoy Platform - Features
Figure 5-8: EDO Platform - Drug Structure
Figure 5-9: OncoPDCs - Excellamol
Figure 5-10: PDPS Platform - PeptiDream
Figure 5-11: Rational Design Based Drug Discovery - Mainline Biosciences
Figure 5-12: pre|CISION(R) Platform - Generations & Features
Figure 5-13: PIP - Mechanism Of Action
Figure 5-14: PIP Platform - TwoStep Toolbox
Figure 5-15: Peptide - Advantages
Figure 5-16: SORT1+ Technology - PDC Structure
Figure 5-17: MPD-1 - Mechanism of Action
Figure 5-18: Bi-XDC Technology - Coherent Biopharma
Figure 5-19: NIPEP-TPP - NIBEC
Figure 7-1: Lutathera - Approval Year By Region
Figure 7-2: Lutathera - Patent Filing & Expiration Year
Figure 7-3: Global - Lutathera Sales (US$ Million), 202021-2025
Figure 7-4: Global - Lutathera Quarterly Sales (US$ Million), 2025
Figure 7-5: Regional - Lutathera Sales (US$ Million), 2025
Figure 7-6: Regional - Lutathera Sales (US$ Million), 2025
Figure 7-7: US - Lutathera Sales (US$ Million), 2023-2025
Figure 7-8: US - Lutathera Quarterly Sales (US$ Million), 2025
Figure 7-9: ROW - Lutathera Sales (US$ Million), 2023-2025
Figure 7-10: ROW - Lutathera Quarterly Sales (US$ Million), 2025
Figure 8-1: Pepaxto/Pepaxti - Approval Year By Region
Figure 8-2: Pepaxti - Patent Filing & Expiration Year
Figure 8-3: Europe - Pepaxti Sales (US$ Million), 2021-2025
Figure 9-1: Global - Peptide Drug Conjugate Clinical Pipeline By Phase (Number of Drugs), 2026 Till 2031
Figure 9-2: Global - Peptide Drug Conjugate Clinical Pipeline By Company (Number of Drugs), 2026 Till 2031
Figure 9-3: Global - Peptide Drug Conjugate Clinical Pipeline By Country (Number of Drugs), 2026 Till 2031
Figure 9-4: Global - Peptide Drug Conjugate Clinical Pipeline By Indication (Number of Drugs), 2026 Till 2031
Figure 9-5: Global - Peptide Drug Conjugate Clinical Pipeline By Priority Status (Number of Drugs), 2026 Till 2031

List of Tables

Table 2-1: Antibody Drug Conjugates v/s Peptide Drug Conjugates
Table 7-1: Lutathera - Recommended Amino Acid Solution Dosing
Table 7-2: Lutathera - Recommended Dosage Modifications For Adverse Reactions
Table 8-1: Pepaxti - Recommended Dose Reduction for Adverse Reactions
Table 8-2: Pepaxti - Recommended Dose Modifications for Adverse Reactions

02-2729-4219

+886-2-2729-4219

License/价格

全球胜肽类药物偶联物市场：市场机会、药物销售、专利、定价、剂量、专有技术和临床试验展望（2031 年）

Global Peptide Drug Conjugate Market Opportunity, Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Clinical Trials Outlook 2031

目录

第一章：调查方法

第二章：胜肽-药物偶联物概述

第三章：胜肽-药物偶联物－结构组成与作用机制

第四章：胜肽-药物偶联物依适应症分類的研究与发展趋势

第五章：全球胜肽类药物偶联物市场展望

第六章：全球胜肽类药物偶联物调查及市场趋势（按地区划分）

第七章：Lutasera－临床与商业性见解

第八章：Pepact/Pepacti——临床和商业性见解

第九章：胜肽类药物偶联物全球临床开发平臺概述

第十章：胜肽类药物偶联物临床试验的全球概况（按公司、国家、适应症和阶段划分）

第十一章市售胜肽类药物偶联物的临床研究结果

第十二章竞争格局